Pfizer faces growth challenges with patent losses and waning COVID sales. Selling an ATM Put option expiring Nov'25 could ...

Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President Donald Trump’s trade war continues to escalate with new tariffs.

The ad concludes by directing viewers to Pfizer’s VaxAssist website to find and schedule a vaccine. Though the company’s logo is prominently ... s vaccine, or “no preference.” ...

Shares of Pfizer Inc. PFE shed 3.49% to $21.84 Tuesday, on what proved to be an all-around poor trading session for the stock ...

March 18 (Reuters) - Pfizer (PFE.N), opens new tab will sell its remaining stake in British consumer healthcare group Haleon (HLN.L), opens new tab, the companies said on Tuesday. Pfizer will sell ...

Pfizer (NYSE:PFE) is undervalued, trading well below its historical and sector averages despite strong non-COVID revenue growth and cost optimizations. Its expanding pipeline in oncology, obesity ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of $34.00. The company’s shares closed yesterday at $22.63.

(Reuters) -Pfizer will sell its remaining stake in British consumer healthcare group Haleon, the companies said on Tuesday. Pfizer will sell about 662 million ordinary shares, or 7.3%, of Haleon ...

March 19 (Reuters) - Drugmaker Pfizer (PFE.N), opens new tab has sold its entire stake in Haleon (HLN.L), opens new tab for about 2.5 billion pounds ($3.24 billion) to institutional investors and ...

Pfizer PFE-1.48%decrease; red down pointing triangle had a problem. Doctors weren’t prescribing its migraine drug Nurtec because they assumed insurance coverage would be too much of a hassle. So ...

With Pfizer’s final stake sale in the bag, the two Big Pharma companies behind Haleon’s genesis have formally parted ways with the standalone consumer health giant. After charting similar ...

But soon the Obama administration came down hard on such 'tax inversion' deals, changing laws such that the deal was no longer attractive to Pfizer. No signs of slowing down Despite some setbacks ...